PRINCETON, N.J., Feb. 1, 2011 /PRNewswire/ — Soligenix, Inc.
(OTC Bulletin Board:
SNGX) (Soligenix or the Company), a late-stage
biopharmaceutical company, announced today that it has appointed
Kevin Horgan, MD, as its Senior Vice President and Chief Medical
Officer. Dr. Horgan is a board-certified gastroenterologist with a
research background in cellular immunology and experience in the
care of patients with inflammatory bowel disease, including
graft-versus-host disease (GVHD). He has had a long and
distinguished career of more than 25 years in both academia and
industry, most notably with Merck, Centocor, and GE Healthcare.
Dr. Horgan will lead Soligenix’s clinical research with
primary focus on the execution and completion of its confirmatory
Phase 3 clinical trial of orBec® (oral beclomethasone
dipropionate or BDP) in the treatment of acute gastrointestinal
(GI) GVHD.
While with Merck, Dr. Horgan led the development of the first
neurokinin-1 receptor antagonist, EMEND®, which was approved
for the prevention of chemotherapy-induced nausea and vomiting. He
subsequently joined Centocor as Vice President of Immunology in
clinical research with responsibility in therapeutics for
inflammatory gastrointestinal diseases. Dr. Horgan was most
recently employed with GE Healthcare as Head of Internal Medicine
R&D in molecular diagnostics. Dr. Horgan has over 40
publications in peer-reviewed journals including the New England
Journal of Medicine, Nature, Journal of Immunology, Journal of
Clinical Oncology, and Gastroenterology.
Dr. Horgan received his medical degree from University College
Cork, Ireland and completed training in internal medicine in
Birmingham, UK (Queen Elizabeth Hospital) and Baltimore, MD (Johns
Hopkins Hospital), followed by an immunology research fellowship
with the National Cancer Institute (NCI) in Bethesda, MD. H
‘/>”/>
